Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy

Bookmark and Share
Published: 18 Feb 2020
Views: 397
Rating:
Save
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Dr Ziad Bakouny speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about a propensity score-based analysis into cytoreductive nephrectomy for mRCC (metastatic renal cell carcinoma) treated with immune checkpoint inhibitors or targeted therapy.

He reports that cytoreductive nephrectomy was still associated with a survival benefit with these immune checkpoint inhibitors.

Dr Bakouny concludes by suggesting that patients with better risk disease and lower metastatic burden can still benefit from cytoreductive nephrectomy.